Trial Profile

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Pembrolizumab Versus Docetaxel with or Without Ramucirumab in Patients with Previously Treated Non-Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Pembrolizumab (Primary) ; Quaratusugene ozeplasmid (Primary) ; Ramucirumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Acclaim-2
Sponsors Genprex

18 Feb 2025 According to ClinicalTrials.gov, this trial was terminated as Enrollment was slow, due to competition with the many other clinical trials for the same patient population, which led to the decision to end enrollment in the trial.
18 Feb 2025 Status changed from active, no longer recruiting to discontinued.
01 Oct 2024 Planned End Date changed from 1 Nov 2028 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com